Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 379-393

  Petersen, Nikolaj H T ^a,e   Olsen, Ole D ^a,e   Groth Pedersen, Line ^a,f   Ellegaard, Anne Marie ^a,g   Bilgin, Mesut ^b   Redmer, Susanne ^c   Ostenfeld, Marie S ^a,h   Ulanet, Danielle ^d   Dovmark, Tobias H ^a   Lønborg, Andreas ^a   Vindeløv, Signe D ^a   Hanahan, Douglas ^d,i   Arenz, Christoph ^c   Ejsing, Christer S ^b   Kirkegaard, Thomas ^a,e   Rohde, Mikkel ^a   Nylandsted, Jesper ^a   Jäättelä, Marja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ORPHAZYME A S   (Denmark)

^f International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^g MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; AMLODIPINE; CHLORMETHINE; CHLOROQUINE; DESIPRAMINE; HEAT SHOCK PROTEIN 70; NORTRIPTYLINE; PHOSPHOLIPID; SIRAMESINE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; TERFENADINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; EMBRYO; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID HYDROLYSIS; LIPID METABOLISM; LIPIDOSIS; LYSOSOME; LYSOSOME MEMBRANE; MALE; MALIGNANT TRANSFORMATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE DRUG DOSE; TUMOR NECROSIS;

EID: 84883627583     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.003     Document Type: Article

References (43)

1. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006, 580:5533-5540.
2. Barceló-Coblijn G., Martin M.L., de Almeida R.F., Noguera-Salvà M.A., Marcilla-Etxenike A., Guardiola-Serrano F., Lüth A., Kleuser B., Halver J.E., Escribá P.V. Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc. Natl. Acad. Sci. USA 2011, 108:19569-19574.
3. Canbay A., Guicciardi M.E., Higuchi H., Feldstein A., Bronk S.F., Rydzewski R., Taniai M., Gores G.J. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J.Clin. Invest. 2003, 112:152-159.
4. Česen M.H., Pegan K., Spes A., Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp. Cell Res. 2012, 318:1245-1251.
5. de Duve C. Lysosomes revisited. Eur. J. Biochem. 1983, 137:391-397.
6. Ejsing C.S., Duchoslav E., Sampaio J., Simons K., Bonner R., Thiele C., Ekroos K., Shevchenko A. Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal. Chem. 2006, 78:6202-6214.
7. Ellegaard A.M., Groth-Pedersen L., Oorschot V., Klumperman J., Kirkegaard T., Nylandsted J., Jäättelä M. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes and inhibit multidrug resistance. Mol. Cancer Ther. 2013, 10.1158/1535-7163.MCT13-0084.
8. Fehrenbacher N., Gyrd-Hansen M., Poulsen B., Felbor U., Kallunki T., Boes M., Weber E., Leist M., Jäättelä M. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 2004, 64:5301-5310.
9. Fehrenbacher N., Bastholm L., Kirkegaard-Sørensen T., Rafn B., Bøttzauw T., Nielsen C., Weber E., Shirasawa S., Kallunki T., Jäättelä M. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res. 2008, 68:6623-6633.
10. Firestone R.A., Pisano J.M., Bonney R.J. Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents. J.Med. Chem. 1979, 22:1130-1133.
11. Foghsgaard L., Wissing D., Mauch D., Lademann U., Bastholm L., Boes M., Elling F., Leist M., Jäättelä M. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J.Cell Biol. 2001, 153:999-1010.
12. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
13. Groth-Pedersen L., Jäättelä M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 2013, 332:265-274.
14. Guicciardi M.E., Miyoshi H., Bronk S.F., Gores G.J. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am. J. Pathol. 2001, 159:2045-2054.
15. Halangk W., Lerch M.M., Brandt-Nedelev B., Roth W., Ruthenbuerger M., Reinheckel T., Domschke W., Lippert H., Peters C., Deussing J. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J.Clin. Invest. 2000, 106:773-781.
16. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25:53-60.
17. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Hendrich A.B., Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr. Drug Targets 2003, 4:23-30.
20. Houseweart M.K., Pennacchio L.A., Vilaythong A., Peters C., Noebels J.L., Myers R.M. Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J.Neurobiol. 2003, 56:315-327.
21. Høyer-Hansen M., Bastholm L., Szyniarowski P., Campanella M., Szabadkai G., Farkas T., Bianchi K., Fehrenbacher N., Elling F., Rizzuto R., et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-β, and Bcl-2. Mol. Cell 2007, 25:193-205.
22. Jaffrézou J.P., Chen G., Durán G.E., Muller C., Bordier C., Laurent G., Sikic B.I., Levade T. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim. Biophys. Acta 1995, 1266:1-8.
23. Jenkins R.W., Canals D., Hannun Y.A. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell. Signal. 2009, 21:836-846.
24. Kinser R.D., Dolph P.J. Cathepsin proteases mediate photoreceptor cell degeneration in Drosophila. Neurobiol. Dis. 2012, 46:655-662.
25. Kirkegaard T., Roth A.G., Petersen N.H., Mahalka A.K., Olsen O.D., Moilanen I., Zylicz A., Knudsen J., Sandhoff K., Arenz C., et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010, 463:549-553.
26. Kolter T., Sandhoff K. Lysosomal degradation of membrane lipids. FEBS Lett. 2010, 584:1700-1712. Published online October 16, 2009. 10.1016/j.febslet.2009.10.021.
27. Kornhuber J., Tripal P., Reichel M., Mühle C., Rhein C., Muehlbacher M., Groemer T.W., Gulbins E. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell. Physiol. Biochem. 2010, 26:9-20.
28. Kreuzaler P.A., Staniszewska A.D., Li W., Omidvar N., Kedjouar B., Turkson J., Poli V., Flavell R.A., Clarkson R.W., Watson C.J. Stat3 controls lysosomal-mediated cell death invivo. Nat. Cell Biol. 2011, 13:303-309.
29. Leist M., Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. 2001, 2:589-598.
30. Luke C.J., Pak S.C., Askew Y.S., Naviglia T.L., Askew D.J., Nobar S.M., Vetica A.C., Long O.S., Watkins S.C., Stolz D.B., et al. An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. Cell 2007, 130:1108-1119.
31. Matsuda S., Okada N., Kodama T., Honda T., Iida T. A cytotoxic type III secretion effector of Vibrio parahaemolyticus targets vacuolar H+-ATPase subunit c and ruptures host cell lysosomes. PLoS Pathog. 2012, 8:e1002803.
32. Ostenfeld M.S., Fehrenbacher N., Høyer-Hansen M., Thomsen C., Farkas T., Jäättelä M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005, 65:8975-8983.
33. Ostenfeld M.S., Høyer-Hansen M., Bastholm L., Fehrenbacher N., Olsen O.D., Groth-Pedersen L., Puustinen P., Kirkegaard-Sørensen T., Nylandsted J., Farkas T., Jäättelä M. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 2008, 4:487-499.
34. Rossi M., Munarriz E.R., Bartesaghi S., Milanese M., Dinsdale D., Guerra-Martin M.A., Bampton E.T., Glynn P., Bonanno G., Knight R.A., et al. Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux. J.Cell Sci. 2009, 122:3330-3339.
35. Sampaio J.L., Gerl M.J., Klose C., Ejsing C.S., Beug H., Simons K., Shevchenko A. Membrane lipidome of an epithelial cell line. Proc. Natl. Acad. Sci. USA 2011, 108:1903-1907.
36. Smith E.L., Schuchman E.H. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J. 2008, 22:3419-3431.
37. Syntichaki P., Xu K., Driscoll M., Tavernarakis N. Specific aspartyl and calpain proteases are required for neurodegeneration in C. elegans. Nature 2002, 419:939-944.
38. Utermöhlen O., Herz J., Schramm M., Krönke M. Fusogenicity ofmembranes: the impact of acid sphingomyelinase on innate immune responses. Immunobiology 2008, 213:307-314.
39. Wolfer A., Wittner B.S., Irimia D., Flavin R.J., Lupien M., Gunawardane R.N., Meyer C.A., Lightcap E.S., Tamayo P., Mesirov J.P., et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc. Natl. Acad. Sci. USA 2010, 107:3698-3703.
40. Yu D., Wolf J.K., Scanlon M., Price J.E., Hung M.C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993, 53:891-898.
41. Zech T., Ejsing C.S., Gaus K., de Wet B., Shevchenko A., Simons K., Harder T. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J. 2009, 28:466-476.
42. Zeidan Y.H., Hannun Y.A. Activation of acid sphingomyelinase byprotein kinase Cdelta-mediated phosphorylation. J.Biol. Chem. 2007, 282:11549-11561.
43. Zeidan Y.H., Jenkins R.W., Korman J.B., Liu X., Obeid L.M., Norris J.S., Hannun Y.A. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr. Drug Targets 2008, 9:653-661.